PMID- 33240992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 18
DP  - 2020 Sep
TI  - Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in 
      lung cancer patients with co-existent tuberculosis.
PG  - 1143
LID - 10.21037/atm-20-5964 [doi]
LID - 1143
AB  - BACKGROUND: This retrospective study evaluated the safety and efficacy of 
      concurrent anti-tuberculosis (TB) and chemotherapy treatment in patients with 
      advanced lung cancer and active TB. METHODS: We retrospectively analyzed patients 
      who were first diagnosed with advanced lung cancer and received first-line 
      chemotherapy in Guangzhou Chest Hospital from 2015 to 2017. Patients were 
      categorized into two groups (2:1): lung cancer patients without active TB (Group 
      A), and lung cancer patients with active TB (Group B). Primary endpoints included 
      adverse events (AEs), objective response rate (ORR), time to treatment failure, 
      and overall survival (OS). RESULTS: A total of 99 patients were eligible (Group 
      A, n=66; Group B, n=33). Grade >/=3 treatment-related AEs, primarily hematologic 
      toxicity, occurred in 39.4% and 51.5% of patients in Groups A and B, 
      respectively. The hypohepatia in both groups was generally at grade 1 or 2, with 
      similar incidences (26% and 27%, respectively). After two cycles of chemotherapy, 
      the ORR was 42.4% and 33.3% in Group A and B, respectively (P=0.383). The median 
      time to treatment failure (TTF) was 7.0 and 5.6 months for Groups A and B, 
      respectively (P=0.175). The median OS was 17.0 and 14.0 months for Groups A and 
      B, respectively (P=0.312). After 3 months of anti-TB treatment, all patients 
      achieved sputum acid-fast bacilli (AFB) smear conversion and absorption on 
      imaging, and the end of follow-up observed no recurrence. CONCLUSIONS: Concurrent 
      anti-TB and chemotherapy treatment did not increase hematological toxicity or 
      hypohepatia in lung cancer patients with pulmonary TB.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Ye, Mei-Feng
AU  - Ye MF
AD  - Guangzhou Medical University, Guangzhou, China.
FAU - Su, Shan
AU  - Su S
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Huang, Zhi-Hao
AU  - Huang ZH
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Zou, Jian-Jun
AU  - Zou JJ
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Su, Duo-Hua
AU  - Su DH
AD  - Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Chen, Xiao-Hui
AU  - Chen XH
AD  - Department of Thoracic Surgery, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Zeng, Long-Feng
AU  - Zeng LF
AD  - Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Liao, Wei-Xiang
AU  - Liao WX
AD  - Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Huang, Hui-Yi
AU  - Huang HY
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Zeng, Yun-Yun
AU  - Zeng YY
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Cen, Wen-Chang
AU  - Cen WC
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Zhang, Xian-Lan
AU  - Zhang XL
AD  - Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Liao, Chun-Xin
AU  - Liao CX
AD  - Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Oncology, Zhujiang Hospital, Guangzhou, China.
FAU - Zhang, Yan-Bin
AU  - Zhang YB
AD  - Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7576042
OTO - NOTNLM
OT  - Lung cancer
OT  - chemotherapy
OT  - pulmonary tuberculosis (pulmonary TB)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-5964). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
PMCR- 2020/09/01
CRDT- 2020/11/26 05:48
PHST- 2020/11/26 05:48 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - atm-08-18-1143 [pii]
AID - 10.21037/atm-20-5964 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Sep;8(18):1143. doi: 10.21037/atm-20-5964.